BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Sreekumar Othumpangat, John D. Noti. A Worldwide Yearly Survey of New Data in Adverse Drug ReactionsSide Effects of Drugs Annual 2018; 40: 345 doi: 10.1016/bs.seda.2018.08.005
2
Marc Pedrosa, Sara Nogales, Mercedes Vergara, Mireia Miquel, Meritxell Casas, Blai Dalmau, Bernat Font, Jordi Sánchez-Delgado. Reactivation of peritoneal and pleural tuberculosis during hepatitis C treatment with direct-acting antiviralsGastroenterología y Hepatología (English Edition) 2019; 42(3): 174 doi: 10.1016/j.gastre.2019.02.019
3
Claudia Colomba, Laura Saporito, Paola Di Carlo, Manlio Tolomeo, Adriana Cervo, Alberto Firenze, Marcello Trizzino, Antonio Cascio. Direct-acting antivirals and visceral leishmaniasis: a case reportBMC Infectious Diseases 2019; 19(1) doi: 10.1186/s12879-019-3947-x
4
Braira Wahid. Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosisJournal of Medical Virology 2019; 91(12): 2195 doi: 10.1002/jmv.25557
5
Takashi Kida, Atsushi Umemura, Shunya Kaneshita, Risa Sagawa, Takuya Inoue, Shogo Toyama, Makoto Wada, Masataka Kohno, Ryo Oda, Tohru Inaba, Yoshito Itoh, Yutaka Kawahito. Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-seriesModern Rheumatology 2019; : 1 doi: 10.1080/14397595.2019.1682787
6
Marc Pedrosa, Sara Nogales, Mercedes Vergara, Mireia Miquel, Meritxell Casas, Blai Dalmau, Bernat Font, Jordi Sánchez-Delgado. Reactivación de tuberculosis peritoneal y pleural durante el tratamiento de la hepatitis C con antivirales de acción directaGastroenterología y Hepatología 2019; 42(3): 174 doi: 10.1016/j.gastrohep.2018.03.003